Despite a slow start to the year for deals, PwC predicts a flurry of activity coming up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

...

Click to view original post